U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07440524) titled 'A Phase 2 Trial of JKN24011 in COPD' on Feb. 23.

Brief Summary: A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of Subcutaneous JKN24011 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Study Start Date: Aug. 01, 2024

Study Type: INTERVENTIONAL

Condition: COPD (Chronic Obstructive Pulmonary Disease)

Intervention: BIOLOGICAL: JKN24011

JKN24011 subcutaneous injection,Q4W

OTHER: Placebo

Placebo subcutaneous injection,Q4W

Recruitment Status: ACTIVE_NOT_RECRUITING

Sponsor: Joincare Pharmaceutical Group Industry Co., Ltd

Published by HT Digital C...